These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 21891998)

  • 41. Mania during treatment of chronic hepatitis C with pegylated interferon and ribavirin.
    Onyike CU; Bonner JO; Lyketsos CG; Treisman GJ
    Am J Psychiatry; 2004 Mar; 161(3):429-35. PubMed ID: 14992966
    [No Abstract]   [Full Text] [Related]  

  • 42. [Pegylated interferon and ribavirin associated retinopathy in patients with hepatitis C].
    Burgueño-Montañés C; Pérez-Álvarez R
    Arch Soc Esp Oftalmol; 2011 Jun; 86(6):193-5. PubMed ID: 21767697
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Pegylated interferon-alfa plus ribavirin therapies for chronic hepatitis C.
    Kanda T; Yokosuka O
    JNMA J Nepal Med Assoc; 2011; 51(181):41-8. PubMed ID: 22335095
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Pegylated interferon alfa-2a. Improved prognosis in hepatitis C].
    MMW Fortschr Med; 2002 Sep; 144(38):59. PubMed ID: 12395712
    [No Abstract]   [Full Text] [Related]  

  • 45. Very short course of triple therapy including telaprevir for chronic hepatitis C: a possible strategy in selected patients.
    Corti G; Salomoni E; Baragli F
    Int J Infect Dis; 2014 Feb; 19():85-6. PubMed ID: 24246771
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Is combination therapy interferon and ribavirin in patients with chronic hepatitis C infection toxic for eyes?
    Mousa N; Besheer T; Gad Y; Elbendary A; Mokbel T; Abdel-Aziz A
    J Ocul Pharmacol Ther; 2013 Apr; 29(3):345-8. PubMed ID: 23113644
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Evaluation of the adverse effect of premature discontinuation of pegylated interferon α-2b and ribavirin treatment for chronic hepatitis C virus infection: results from Kyushu University Liver Disease Study.
    Ogawa E; Furusyo N; Kajiwara E; Takahashi K; Nomura H; Tanabe Y; Satoh T; Maruyama T; Nakamuta M; Kotoh K; Azuma K; Dohmen K; Shimoda S; Hayashi J;
    J Gastroenterol Hepatol; 2012 Jul; 27(7):1233-40. PubMed ID: 22098185
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Side effects of therapy for chronic hepatitis C.
    Russo MW; Fried MW
    Gastroenterology; 2003 May; 124(6):1711-9. PubMed ID: 12761728
    [No Abstract]   [Full Text] [Related]  

  • 49. Effect of ribavirin in genotype 1 patients with hepatitis C responding to pegylated interferon alfa-2a plus ribavirin.
    Bronowicki JP; Ouzan D; Asselah T; Desmorat H; Zarski JP; Foucher J; Bourlière M; Renou C; Tran A; Melin P; Hézode C; Chevalier M; Bouvier-Alias M; Chevaliez S; Montestruc F; Lonjon-Domanec I; Pawlotsky JM
    Gastroenterology; 2006 Oct; 131(4):1040-8. PubMed ID: 17030174
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Treatment of chronic hepatitis C in patients with glucose-6-phosphate dehydrogenase deficiency: is ribavirin harmful?
    Balestrieri C; Serra G; Cauli C; Chessa L; Balestrieri A; Farci P
    Blood; 2006 Apr; 107(8):3409-10. PubMed ID: 16597599
    [No Abstract]   [Full Text] [Related]  

  • 51. [Side effect of pegylated-interferon treatment in chronic C hepatitis: agranulocytosis].
    Halász T; Farkas A; Tolvaj G; Horváth G
    Orv Hetil; 2006 Feb; 147(7):321-4. PubMed ID: 17489160
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Cytopenias during treatment of HIV-HCV-coinfection with pegylated interferon and ribavirin: safety analysis of the OPERA study.
    Pontali E; Angeli E; Cattelan AM; Maida I; Nasta P; Verucchi G; Caputo A; Iannacone C; Puoti M
    Antivir Ther; 2015; 20(1):39-48. PubMed ID: 24831457
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Summaries for patients. Duration and dose of antiviral treatment for chronic hepatitis C.
    Ann Intern Med; 2004 Mar; 140(5):I67. PubMed ID: 14996694
    [No Abstract]   [Full Text] [Related]  

  • 54. [Pegylated-interferon alpha plus ribavirin-induced subacute thyroiditis in chronic hepatitis C].
    Abellán Galiana P; Pérez-Lázaro A; Aguilera Sancho-Tello V; Merino Torres JF; Berenguer Haym M; Piñón Sellés F
    Endocrinol Nutr; 2009 Mar; 56(3):136-9. PubMed ID: 19627727
    [TBL] [Abstract][Full Text] [Related]  

  • 55.  Pegylated interferon, but not conventional interferon therapy induced severe skin lesions.
    Li Z; Ji F; Zheng Y; An J; Peng Z
    Ann Hepatol; 2012; 11(4):570-1. PubMed ID: 22700642
    [No Abstract]   [Full Text] [Related]  

  • 56. Comparison of high ribavirin induction versus standard ribavirin dosing, plus peginterferon-α for the treatment of chronic hepatitis C in HIV-infected patients: the PERICO trial.
    Labarga P; Barreiro P; da Silva A; Guardiola JM; Rubio R; Aguirrebengoa K; Miralles P; Portu J; Téllez MJ; Morano L; Castro A; Pineda JA; Terrón A; Hernández-Quero J; Mariño A; Ríos MJ; Echeverría S; Asensi V; Vispo E; Soriano V;
    J Infect Dis; 2012 Sep; 206(6):961-8. PubMed ID: 22807523
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Safety of peginterferon alfa-2a plus ribavirin in a large multinational cohort of chronic hepatitis C patients.
    Lee SS; Roberts SK; Berak H; Dusheiko GM; Harley HA; Gane EJ; Husa P; Horsmans YJ; Hadziyannis SJ; Jenny Heathcote E; Messinger D; Tatsch F; Han KH; Ferenci P
    Liver Int; 2012 Sep; 32(8):1270-7. PubMed ID: 22621707
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The importance of a prior psychiatric examination in pegylated interferon and ribavirin combination treatment for chronic hepatitis C.
    Kuhara K; Ide T; Uchimura N; Kumashiro R; Arinaga T; Miyajima I; Murashima S; Ogata K; Kuwahara R; Amano K; Fujimoto Y; Sakai K; Ishii K; Morita Y; Shirachi M; Sata M
    Kurume Med J; 2012; 59(3-4):39-44. PubMed ID: 23823013
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Randomized study of peginterferon-alpha2a plus ribavirin vs peginterferon-alpha2b plus ribavirin in chronic hepatitis C.
    Rumi MG; Aghemo A; Prati GM; D'Ambrosio R; Donato MF; Soffredini R; Del Ninno E; Russo A; Colombo M
    Gastroenterology; 2010 Jan; 138(1):108-15. PubMed ID: 19766645
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Efficacy and safety of peginterferon alfa-2a and ribavirin treatment of chronic hepatitis C in the Republic of Serbia].
    Božić M; Bojović K; Fabri M; Nožić D; Trkulja B; Milošević I
    Srp Arh Celok Lek; 2012; 140(7-8):448-55. PubMed ID: 23092029
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.